Auckland Cancer Society Research Centre, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
Eur J Med Chem. 2013 Apr;62:738-44. doi: 10.1016/j.ejmech.2013.01.047. Epub 2013 Feb 9.
High expression of the aldo-keto reductase enzyme AKR1C3 in the human prostate and breast has implicated it in the development and progression of leukemias and of prostate and breast cancers. Inhibitors are thus of interest as potential drugs. Most inhibitors of AKR1C3 are carboxylic acids, whose transport into cells is likely dominated by carrier-mediated processes. We describe here a series of (piperidinosulfonamidophenyl)pyrrolidin-2-ones as potent (<100 nM) and isoform-selective non-carboxylate inhibitors of AKR1C3. Structure-activity relationships identified the sulfonamide was critical, and a crystal structure showed the 2-pyrrolidinone does not interact directly with residues in the oxyanion hole. Variations in the position, co-planarity or electronic nature of the pyrrolidinone ring severely diminished activity, as did altering the size or polarity of the piperidino ring. There was a broad correlation between the enzyme potencies of the compounds and their effectiveness at inhibiting AKR1C3 activity in cells.
醛酮还原酶 1C3(aldo-keto reductase enzyme 1C3,AKR1C3)在人类前列腺和乳腺中的高表达表明其与白血病以及前列腺癌和乳腺癌的发生和发展有关。因此,抑制剂作为潜在药物受到关注。AKR1C3 的大多数抑制剂为羧酸,其进入细胞的运输可能主要由载体介导的过程控制。我们在这里描述了一系列(哌啶磺酰胺基苯)吡咯烷-2-酮,它们是 AKR1C3 的有效(<100 nM)和同工酶选择性的非羧酸抑制剂。构效关系确定磺酰胺是关键的,晶体结构显示 2-吡咯烷酮不会与氧阴离子穴中的残基直接相互作用。吡咯烷酮环的位置、共面性或电子性质的变化严重降低了活性,改变哌啶环的大小或极性也是如此。化合物的酶活性与其在细胞中抑制 AKR1C3 活性的效果之间存在广泛的相关性。